iECURE, a private clinical-stage genome editing company, reported preliminary safety observations fr

Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 35.9% to $7.3 during Tuesday's

PBGENE-DMD is Precision's wholly owned in vivo gene editing program designed to durably improve

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi

PBGENE-HBV's liver biopsy data provides unusually direct evidence that ARCUS is editing the viral re

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its nove

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi

– Leadership updates come as Precision advances its lead programs, PBGENE-HBV for chronic hepatitis

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL

Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being high

Also in its updated corporate deck, the Company announced activation of a second clinical site at Wa

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its nove

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi

Oppenheimer analyst Joseph Thome initiates coverage on Precision BioSciences (NASDAQ:DTIL) with a

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Precision BioSciences (NASDAQ:DTIL

Precision BioSciences (DTIL) trades up 10.55% premarket. Bullish moving averages and new data point

- New biopsy data demonstrate thatPBGENE-HBV directly eliminated cccDNA through its primary mechanis

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its nove

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi

– New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in ske

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi

Precision BioSciences (DTIL) came out with a quarterly loss of $0.34 per share versus the Zacks Cons

Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.75) per share which missed the

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi

iECURE has licensed the ARCUS® nuclease from Precision BioSciences for four gene insertion programs

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene edi

Jones Trading analyst Catherine Novack assumes Precision BioSciences (NASDAQ:DTIL) with a Buy rat

- France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patien

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel

– Fast Track designation aims to facilitate development and expedite review of drugs, such as PBGENE

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel

– U.S. FDA Study May Proceed notification enables initiation of clinical trial site activation for t

Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates exp

Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates exp

Reached alignment with FDA on endpoints, comparators and sample size for the ongoing OTC-HOPE study

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel

Precision BioSciences, Inc. (NASDAQ:DTIL) ("Precision"), a clinical stage gene editing compa